Manuscripts and Publications

Filters: First Letter Of Last Name is K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, D Harris R, Mulligan K, Zimet G et al..  2017.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, D Harris R, Mulligan K, Zimet G et al..  2017.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB.  2012.  Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
Boyer CB, Greenberg L, Korelitz J, Harper GW, Stewart-Campbell R, Straub D, Sanders R, Reid L-H, Futterman D, Lee S et al..  2019.  Sexual Partner Characteristics, Relationship Type, and HIV Risk Among a Community Venue-based Sample of Urban Adolescent and Young Adult Men Who Have Sex with Men.. Youth Soc. 51(2):219-246.
Wilson PA, Kahana SY, Fernandez MIsabel, Harper GW, Mayer K, Wilson CM, Hightow-Weidman LB.  2016.  Sexual Risk Behavior Among Virologically Detectable Human Immunodeficiency Virus-Infected Young Men Who Have Sex With Men.. JAMA Pediatr. 170(2):125-31.
Shannon CL, Keizur EM, Fehrenbacher A, Wood-Palmer D, Ramos W, Koussa M, Fournier J, Lee S-J, Patel D, Akabike WN et al..  2019.  Sexually Transmitted Infection Positivity Among Adolescents With or at High-Risk for Human Immunodeficiency Virus Infection in Los Angeles and New Orleans.. Sex Transm Dis. 46(11):737-742.
Shannon CL, Keizur EM, Fehrenbacher A, Wood-Palmer D, Ramos W, Koussa M, Fournier J, Lee S-J, Patel D, Akabike WN et al..  2019.  Sexually Transmitted Infection Positivity Among Adolescents With or at High-Risk for Human Immunodeficiency Virus Infection in Los Angeles and New Orleans.. Sex Transm Dis. 46(11):737-742.
Shannon CL, Keizur EM, Fehrenbacher A, Wood-Palmer D, Ramos W, Koussa M, Fournier J, Lee S-J, Patel D, Akabike WN et al..  2019.  Sexually Transmitted Infection Positivity Among Adolescents With or at High-Risk for Human Immunodeficiency Virus Infection in Los Angeles and New Orleans.. Sex Transm Dis. 46(11):737-742.
Rudy BJ, Sleasman J, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, Ahmad S, Cunningham CK.  2009.  Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.. AIDS Res Hum Retroviruses. 25(6):555-61.
Williams JC, Zhang X, Karki M, Chi Y-Y, Wallet SM, Rudy BJ, Nichols SL, Goodenow MM, Sleasman JW.  2018.  Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.. J Leukoc Biol. 103(4):671-680.
Rotheram MJane, Fernandez MIsabel, Lee S-J, Abdalian SEllen, Kozina L, Koussa M, Comulada WScott, Klausner JD, Arnold EMayfield, Ocasio MA et al..  2019.  Strategies to Treat and Prevent HIV in the United States for Adolescents and Young Adults: Protocol for a Mixed-Methods Study.. JMIR Res Protoc. 8(1):e10759.
Rotheram MJane, Fernandez MIsabel, Lee S-J, Abdalian SEllen, Kozina L, Koussa M, Comulada WScott, Klausner JD, Arnold EMayfield, Ocasio MA et al..  2019.  Strategies to Treat and Prevent HIV in the United States for Adolescents and Young Adults: Protocol for a Mixed-Methods Study.. JMIR Res Protoc. 8(1):e10759.
Rotheram MJane, Fernandez MIsabel, Lee S-J, Abdalian SEllen, Kozina L, Koussa M, Comulada WScott, Klausner JD, Arnold EMayfield, Ocasio MA et al..  2019.  Strategies to Treat and Prevent HIV in the United States for Adolescents and Young Adults: Protocol for a Mixed-Methods Study.. JMIR Res Protoc. 8(1):e10759.
Kahana SY, Jenkins RA, Bruce D, Fernandez MI, Hightow-Weidman LB, Bauermeister JA.  2016.  Structural Determinants of Antiretroviral Therapy Use, HIV Care Attendance, and Viral Suppression among Adolescents and Young Adults Living with HIV.. PLoS One. 11(4):e0151106.
Agwu AL, Bethel J, Hightow-Weidman LB, Sleasman JW, Wilson CM, Rudy B, Kapogiannis BG.  2012.  Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.. AIDS Patient Care STDS. 26(4):193-6.
Brennan J, Kuhns LM, Johnson AK, Belzer M, Wilson EC, Garofalo R.  2012.  Syndemic theory and HIV-related risk among young transgender women: the role of multiple, co-occurring health problems and social marginalization.. Am J Public Health. 102(9):1751-7.
T
Carballo-Diéguez A, Giguere R, Dolezal C, Chen BA, Kahn J, Zimet G, Mabragaña M, Leu C-S, McGowan I.  2012.  "Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.. AIDS Behav. 16(7):1761-74.
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW.  2019.  Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.. AIDS Res Hum Retroviruses. 35(8):746-754.
LeGrand S, Knudtson K, Benkeser D, Muessig K, Mcgee A, Sullivan PS, Hightow-Weidman L.  2018.  Testing the Efficacy of a Social Networking Gamification App to Improve Pre-Exposure Prophylaxis Adherence (P3: Prepared, Protected, emPowered): Protocol for a Randomized Controlled Trial.. JMIR Res Protoc. 7(12):e10448.
Swendeman D, Arnold EMayfield, Harris D, Fournier J, W Comulada S, Reback C, Koussa M, Ocasio M, Lee S-J, Kozina L et al..  2019.  Text-Messaging, Online Peer Support Group, and Coaching Strategies to Optimize the HIV Prevention Continuum for Youth: Protocol for a Randomized Controlled Trial.. JMIR Res Protoc. 8(8):e11165.
Swendeman D, Arnold EMayfield, Harris D, Fournier J, W Comulada S, Reback C, Koussa M, Ocasio M, Lee S-J, Kozina L et al..  2019.  Text-Messaging, Online Peer Support Group, and Coaching Strategies to Optimize the HIV Prevention Continuum for Youth: Protocol for a Randomized Controlled Trial.. JMIR Res Protoc. 8(8):e11165.
Alcantara L, Harper GW, Keys CB.  2015.  "There's Gotta be Some Give and Take": Community Partner Perspectives on Benefits and Contributions associated with Community Partnerships for Youth.. Youth Soc. 47(4):462-485.
Gilliam PP, Ellen JM, Leonard L, Kinsman S, Jevitt CM, Straub DM.  2011.  Transition of adolescents with HIV to adult care: characteristics and current practices of the adolescent trials network for HIV/AIDS interventions.. J Assoc Nurses AIDS Care. 22(4):283-94.
Tanner AE, Philbin MM, Duval A, Ellen J, Kapogiannis B, J Fortenberry D.  2016.  Transitioning HIV-Positive Adolescents to Adult Care: Lessons Learned From Twelve Adolescent Medicine Clinics.. J Pediatr Nurs. 31(5):537-43.
V
Giguere R, Carballo-Diéguez A, Ventuneac A, Mabragaña M, Dolezal C, Chen BA, Kahn JA, Zimet GD, McGowan I.  2012.  Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.. Cult Health Sex. 14(2):151-66.
Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM.  2006.  Vitamin D status in adolescents and young adults with HIV infection.. Am J Clin Nutr. 83(5):1135-41.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, D Harris R et al..  2018.  Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.. Clin Infect Dis. 66(2):220-228.

Pages